[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612170":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":28,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Herlev Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients suspected of pancreatic cancer",null,[12],"Other: observational study",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"observational study","Aprox. 300 patients suspected of pancreatic cancer. Of those, minimum of 50 patients with histologically confirmed PDAC in each of the stages I-II, III and IV, as some of the participants will be diagnosed with a non-malignant disease and will constitute the control group.",[9],[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Bojan Kovacevic, ph.d., MD","CONTACT","0045 3868 6312","bojan.kovacevic@regionh.dk",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Louise Maegaard, MSc, RN","90045 3868 9879","louise.maegaard@regionh.dk",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Herlev og Gentofte Hospital","RECRUITING","Herlev","Capital Region","2730","Denmark","DK",{"type":38,"coordinates":39},"Point",[40,41],12.43998,55.72366,{"lat":41,"lon":40},[44],{"name":45,"role":21,"phone":46,"phoneExt":10,"email":23},"Bojan Kovacevic, MD, ph.d.","0045 38686312",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Bojan Kovacevic","MD, ph.d.",[52],{"name":53,"class":6},"Danish Cancer Society","100612170","the-role-of-microbiota-in-pancreatic-cancer-and-precursor-lesions-100612170",false,"NCT07250100","The Role of Microbiota in Pancreatic Cancer and Precursor Lesions","MICROPAC","Inclusion Criteria:\n\n* Patients with a suspected lesion (solid\u002Fcystic) in the pancreas undergoing diagnostic or therapeutic endoscopic procedure\n* Age of 18 years or above\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Contraindications for endoscopic or surgical procedure, such as uncorrected coagulopathy","ALL","18 Years",{"count":64,"type":65},300,"ESTIMATED","OBSERVATIONAL","This is a prospective observational study aiming to investigate the microbiome in patients suspected of having pancreatic cancer. The purpose is to enhance diagnostic accuracy by developing screening protocols for high-risk individuals, identifying specific microbial biomarkers, and improving prognostic criteria to optimize treatment response.\n\nParticipants will be asked to complete a questionnaire, provide oral and fecal swabs, and-if clinically indicated-1-2 pancreatic biopsies will be collected.",[69,70],"Pancreatic Cancer","Microbiome","2025-11-18",{"date":73,"type":74},"2025-11-26","ACTUAL",{"date":76,"type":74},"2025-11-01",{"date":78,"type":65},"2037-12",{"name":5,"class":6},1]